Ken Griffin Pharvaris N.V. Call Options Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding PHVS
# of Institutions
37Shares Held
37.8MCall Options Held
0Put Options Held
0-
General Atlantic LLC New York, NY7.53MShares$188 Million4.48% of portfolio
-
Foresite Capital Management Iv, LLC Larkspur, CA4.29MShares$107 Million54.23% of portfolio
-
Ven Bio Partners LLC San Francisco, CA4.29MShares$107 Million45.57% of portfolio
-
Viking Global Investors LP3.65MShares$91.4 Million0.27% of portfolio
-
Vr Adviser, LLC New York, NY3.4MShares$84.9 Million7.0% of portfolio
About Pharvaris N.V.
- Ticker PHVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,766,000
- Market Cap $844M
- Description
- Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, r...